December 2021
·
58 Reads
European Neuropsychopharmacology
This page lists works of an author who doesn't have a ResearchGate profile or hasn't added the works to their profile yet. It is automatically generated from public (personal) data to further our legitimate goal of comprehensive and accurate scientific recordkeeping. If you are this author and want this page removed, please let us know.
December 2021
·
58 Reads
European Neuropsychopharmacology
... 528). While one study estimated that one in two OCD patients benefited from antipsychotics (Conti et al., 2024), a more recent review found efficacy in only one in three patients (Thamby & Jaisoorya, 2019). Indeed, a recent Cochrane review (Komossa et al., 2010) found no effect of olanzapine augmentation on OCD and only some (not fully conclusive) evidence that adding quetiapine or risperidone to antidepressants increases efficacy. ...
February 2024
Human Psychopharmacology Clinical and Experimental
... Thus, identifying and managing the most critical side effects encourages patients to take medications regularly and adhere to the course of treatment. This situation increases treatment compliance and may positively affect treatment outcomes [10]. Therefore, priority should be given to the more important ones, among these side effects. ...
May 2023
... In accordance with the literature, a score of 10 or above is a reliable cut-off to assign a provisional diagnosis of major depression [26]. The PHQ-9 has been largely used as a screening tool for depression in primary care settings, as well as to assess depressive symptoms in healthcare workers during COVID-19 [27,28]. ...
February 2023